Dissertation/Thesis Abstract

Ketafusion, LLC
by Tarrillion, Doris, M.S., California State University, Long Beach, 2019, 69; 13903920
Abstract (Summary)

Depression is a debilitating and devastating mood disorder that can affect all ages and people of all races across all socioeconomic statuses. Conventional antidepressant medications only give one-third of relief from symptoms of depression, leaving the remainder to suffer from treatment-resistant depression (TRD). For the past two decades, researchers have looked into ketamine for the treatment of depression with promising results. All studies have validated that the intravenous (IV) use of ketamine is now the breakthrough treatment for TRD. This creates demand and a dire need to those are suffering from treatment-resistant depression. Ketafusion, LLC will specialize in delivery of safe and affordable intravenous ketamine infusion in the heart of Los Angeles County. It will provide personalized concierge care throughout every step of the treatment and recovery process to improve the quality of life of individuals battling TRD.

Supplemental Files

Some files may require a special program or browser plug-in. More Information

Indexing (document details)
Advisor: Gotz, Cindy
Commitee: Gerard, Nathan, Sinay, Tony
School: California State University, Long Beach
Department: Health Care Administration
School Location: United States -- California
Source: MAI 81/3(E), Masters Abstracts International
Source Type: DISSERTATION
Subjects: Health care management
Keywords: Mental depression, Medical treatment, Intravenous therapy
Publication Number: 13903920
ISBN: 9781088322253
Copyright © 2019 ProQuest LLC. All rights reserved. Terms and Conditions Privacy Policy Cookie Policy
ProQuest